Literature DB >> 26933261

Behavioral response and cost comparison of manual versus pharmacologic restraint protocols in healthy dogs.

Michele Barletta1, Marc Raffe1.   

Abstract

Although sedatives are routinely administered to dogs for diagnostic and minimally invasive procedures, manual restraint is often used. The study compared intra-procedural behavioral response, scored on a 100-point, visual analog scale, and cost of restraint in healthy dogs given 1 of 5 treatments: manual restraint, dexmedetomidine at 125 μg/m(2) (Dex 125) or 375 μg/m(2) (Dex 375), Dex 125 plus butorphanol at 0.4 mg/kg (Dex 125 + Bu), or Dex 375 plus butorphanol at 0.4 mg/kg (Dex 375 + Bu). Mean behavioral response scores in dogs declined from baseline in the manual restraint group and improved in a linear fashion in the group order Dex 125, Dex 375, Dex 125 + Bu, and Dex 375 + Bu. Dexmedetomidine at 375 μg/m(2) or at 125 μg/m(2) or at 375 μg/m(2) in combination with butorphanol produced the best intra-procedural behavioral response. The cost of sedative drugs was offset by the opportunity cost of diverting personnel from revenue-generating activity to manual restraint.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26933261      PMCID: PMC4751764     

Source DB:  PubMed          Journal:  Can Vet J        ISSN: 0008-5286            Impact factor:   1.008


  25 in total

1.  Can the real opportunity cost stand up: displaced services, the straw man outside the room.

Authors:  Simon Eckermann; Brita Pekarsky
Journal:  Pharmacoeconomics       Date:  2014-04       Impact factor: 4.981

2.  Clinical effects and pharmacokinetics of medetomidine and its enantiomers in dogs.

Authors:  E Kuusela; M Raekallio; M Anttila; I Falck; S Mölsä; O Vainio
Journal:  J Vet Pharmacol Ther       Date:  2000-02       Impact factor: 1.786

3.  Comparison of the behavioral and neurochemical effects of the two optical enantiomers of medetomidine, a selective alpha-2-adrenoceptor agonist.

Authors:  E MacDonald; M Scheinin; H Scheinin; R Virtanen
Journal:  J Pharmacol Exp Ther       Date:  1991-11       Impact factor: 4.030

4.  Central alpha 2-adrenoceptors are highly stereoselective for dexmedetomidine, the dextro enantiomer of medetomidine.

Authors:  J M Savola; R Virtanen
Journal:  Eur J Pharmacol       Date:  1991-03-26       Impact factor: 4.432

Review 5.  Medetomidine and dexmedetomidine: a review of cardiovascular effects and antinociceptive properties in the dog.

Authors:  Joanna C Murrell; Ludo J Hellebrekers
Journal:  Vet Anaesth Analg       Date:  2005-05       Impact factor: 1.648

6.  Evaluation of dexmedetomidine and ketamine in combination with opioids as injectable anesthesia for castration in dogs.

Authors:  Michele Barletta; Brenda R Austin; Jeff C Ko; Mark E Payton; Ann B Weil; Tomohito Inoue
Journal:  J Am Vet Med Assoc       Date:  2011-05-01       Impact factor: 1.936

7.  Clinical efficacy and safety of dexmedetomidine and buprenorphine, butorphanol or diazepam for canine hip radiography.

Authors:  M K Leppänen; B C McKusick; M M Granholm; F C Westerholm; R Tulamo; C E Short
Journal:  J Small Anim Pract       Date:  2006-11       Impact factor: 1.522

8.  The sedative effects of low-dose medetomidine and butorphanol alone and in combination intravenously in dogs.

Authors:  Nicolas M Girard; Elizabeth A Leece; Jm Cardwell; Vicki J Adams; Jacqueline C Brearley
Journal:  Vet Anaesth Analg       Date:  2010-01       Impact factor: 1.648

Review 9.  A review of the physiological effects of alpha2-agonists related to the clinical use of medetomidine in small animal practice.

Authors:  Melissa D Sinclair
Journal:  Can Vet J       Date:  2003-11       Impact factor: 1.008

10.  24-hour Holter-monitoring in the perianaesthetic period in dogs premedicated with dexmedetomidine.

Authors:  E Kuusela; M Raekallio; H Hietanen; J Huttula; O Vainio
Journal:  Vet J       Date:  2002-11       Impact factor: 2.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.